AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM: PROBLEM STATEMENT AND PROSPECTS

Cover Page

Abstract


This review highlights the achievements in the field of autoimmune diseases of the nervous system over the last 15 years. It became possible to deepen the understanding of medical and social significance of these diseases, form the concept of nosologic unit heterogeneity, describe new and atypical forms of demyelinating diseases of the central and peripheral nervous system, autoimmune diseases of the neuromuscular synapse. Also, it is important to mention, that the new antigens were identified, the diagnostic panel of autoantibodies was developed and put into practice. Furthermore, the clinical practice guidelines for the diagnosis and management of patients were developed, the new drugs were tested and included in these guidelines. The scientists of the biggest Russian neurological centre, Research Centre of Neurology (Moscow), developed a vaccine for immunotherapy of multiple sclerosis, studied pathomorphosis of Guillain–Barre syndrome, specified the components of its pathogenesis, improved the programs of pathogenetic therapy, which led to the decrease in mortality from 30 to 3%, helped to decrease the AVL period by 2 times, hasten the recovery of independent walking by 2.5 times. Nowadays different biomarkers of diseases of the central and peripheral nervous system are studied and modern technologies in neurorehabilitation are applied.

 


M. A. Piradov

Research Centre of Neurology, Moscow, Russian Federation

Author for correspondence.
Email: dir@neurology.ru

Russian Federation PhD, professor, corresponding member of RAS, Director of Research Centre of Neurology. Address: 80, Volokolamskoe Highway, Moscow, 125367, tel.: +7 (495) 290-20-03

N. A. Suponeva

Research Centre of Neurology, Moscow, Russian Federation

Email: reneurology@neurology.ru

Russian Federation PhD, Head of the Department of Neurorehabilitation and Physiatrics of Research Centre of Neurology. Address: 80, Volokolamskoe Highway, Moscow, 125367, tel.: +7 (495) 290-20-03

  1. Autoimmunnye zabolevaniya v nevrologii. Klinicheskoe rukovodstvo. V 2 tomakh. Pod red. I.A. Zavalishina, M.A. Piradova, A.N. Boiko, S.S. Nikitina, N.N. Spirina, A.V. Peresedovoi [Autoimmune Neurological Diseases. Clinical Manual. In 2 vol. Edited by I.A. Zavalishin, M.A. Piradov, A.N. Boiko, S.S. Nikitin, N.N. Spirin, A.V. Peresedova] Moscow, Zdorov'e cheloveka, 2014. 400 p.
  2. Atlas country resources for neurological disorders. Geneva: World Health Organization. 2004. 60 p.
  3. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. In: Global Burden of Disease and Injury Series, Vol. I. C.J.L. Murray, A.D. Lopez (eds.). Cambridge, MA, Harvard School of Public Health on behalf of the World Health Organization and The World Bank. 1996. 44 р.
  4. Peresedova A.V., Zavalishin I.A. Multiple sclerosis: current state. Annaly klinicheskoi i eksperimental'noi nevrologii = Annals of clinical and experimental neurology. 2009;1:43–47.
  5. Piradov M.A., Suponeva N.A. Sindrom Giiena-Barre: diagnostika i lechenie. Ruk-vo dlya vrachei [Guillain-Barre Syndrome: Diagnosis and Treatment. Clinical Manual]. Moscow, MEDpress,-inform, 2011. 200 p.
  6. Williams K.A., Swedo S.E. Post-infectious autoimmune disorders: Sydenham's chorea, PANDAS and beyond. Brain Res. 2014;pii:S0006–8993(14)01344–4. doi: 10.1016/j.brainres.2014.09.071.
  7. Berer K., Krishnamoorthy G. Microbial view of central nervous system autoimmunity. FEBS Lett. 2014;588(22):4207–4213. doi: 10.1016/j.febslet.2014.04.007.
  8. Segal B.M. Neurosarcoidosis: diagnostic approaches and therapeutic strategies. Curr. Opin. Neurol. 2013;26(3):307–313. doi: 10.1097/WCO.0b013e3283608459.
  9. Soliven B. Animal Models of Autoimmune Neuropathy. Oxford J. Sci. & Math. ILAR J. 2013;54(3):282–290.
  10. Jung S., Gaupp S., Korn T., Kollner G., Hartung H.P., Toyka K.V. Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization. J. Neurosci. Res. 2004; 75: 524–535.
  11. Sanders D.B., Guptill J.T. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum (Minneap Minn). 2014;20(5 Peripheral Nervous System Disorders):1413–1425. doi: 10.1212/01.CON.0000455873.30438.9b.
  12. Skaper S.D., Leon A., Toffano G. Mol Ganglioside function in the development and repair of the nervous system. From basic science to clinical application. Neurobiol. 1989;3(3):173–199.
  13. Alvermann S., Hennig C., Stüve O., Wiendl H., Stangel M. Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. JAMA Neurol. 2014;71(7):905–912. doi: 10.1001/jamaneurol.2014.395.
  14. Alexopoulos H., Dalakas M.C. Immunology of stiff person syndrome and other GAD-associated neurological disorders. Exp. Rev. Clin. Immunol. 2013;9(11):1043–1053. doi: 10.1586/1744666X.2013.845527.
  15. Simmons S.B., Pierson E.R., Lee S.Y., Goverman J.M. Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol. 2013;34(8):410–422. doi: 10.1016/j.it.2013.04.006.
  16. van den Berg B., Walgaard C., Drenthen J., Fokke C., Jacobs B.C., van Doorn P.A. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 2014; 10 (8): 469–482. doi: 10.1038/nrneurol.2014.121.
  17. Sieb J.P. Myasthenia gravis: an update for the clinician. Clin. Exp. Immunol. 2014; 175 (3): 408–418. doi: 10.1111/cei.12217.
  18. Iwanowski P., Losy J. Immunological differences between classical phenothypes of multiple sclerosis. J. Neurol. Sci. 2015; 349 (1–2): 10–14. doi: 10.1016/j.jns.2014.12.035.
  19. Mathey E.K., Park S.B., Hughes R.A., Pollard J.D., Armati P.J., Barnett M.H., Taylor B.V., Dyck P.J., Kiernan M.C., Lin C.S. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J. Neurol. Neurosurg. Psychiatry. 2015;pii:jnnp-2014–309697. doi: 10.1136/jnnp-2014-309697.
  20. Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J. Autoimmun. 2014;48–49:134–142. doi: 10.1016/j.jaut.2014.01.022.
  21. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society ― First Revision. J. Peripher. Nerv. Syst. 2010;15:1–9.
  22. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society ― first revision. J. Peripher. Nerv. Syst. 2010;15:295–301.
  23. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society ― first revision. J. Peripher. Nerv. Syst. 2010;15(3):185–195. doi: 10.1111/j.1529-8027.2010.00278.x.
  24. Skeie G. O., Apostolski S., Evoli A., Gilhus N. E., Illa I., Harms L., Hilton-Jones D., Melms A., Verschuuren J., Horge H.W. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 2010;17(7):893–902. doi: 10.1111/j.1468-1331.2010.03019.x.
  25. Montalban X., Tintoré M. Multiple sclerosis in 2013: novel triggers, treatment targets and brain atrophy measures. Nat. Rev. Neurol. 2014;10(2):72–73. doi: 10.1038/nrneurol.2013.274.
  26. Peresedova A.V., Zavalishin I.A. Multiple sclerosis: current state. Annaly klinicheskoi i eksperimental'noi nevrologii = Annals of clinical and experimental neurology. 2009;3(1):43–47.
  27. Eliseeva D.A., Peresedova A.V., Askarova L.Sh., Adarcherva L.S., Zakharova M.N., Stoida N.I., Vasil'ev A.V., Trifonova O.V., Zavalishin I.A. Experience with Fingolimod in the Treatment of Relapsing-Remitting Multiple Sclerosis in Russia. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2014;58(6):24–29.
  28. Vorob'eva A.A., Simaniv T.O., Zakharova M.N., Zavalishin I.A., Peresedova A.V. Experience of Using Natalizumab (Tysabri) at the Research Center of Neurology. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2014;58(6):4–11.
  29. Eliseeva D.D., Zavalishin I.A., Bykovskaya S.N., Fedorova T.N., Karandashov E.N., Trunova O.A. Regulatory T-cells CD4+CD25+Foxр3+ in patients with remitting multiple sclerosis. Annaly klinicheskoi i eksperimental'noi nevrologii = Annals of clinical and experimental neurology. 2011;5(2):9–13.
  30. Chervyakov A.V., Poidasheva A.G., Korzhova Yu.E., Suponeva N.A., Chernikova L.A., Piradov M.A. Modern therapeurtic opportunities of repeated transcranial magnetic stimulation in treatment of nervous system diseases. Russkii meditsinskii zhurnal = Russian medical journal. 2014;22(22):1567–1572.
  31. Zavalishin I.A., Peresedova A.V., Stoida N.I., Gur'yanova O.E., Arzumanyan N.Sh., Alekseeva N.S., Eliseeva D.D., Gulevskaya T.S., Bryukhov V.V. Diagnosis and treatment of multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova = S.S. Korsakov journal of Neurology and Psychiatry. 2011;111(6):89–96.
  32. Korzhova Yu.E., Chervyakov A.V., Poidasheva A.G., Peresedova A.V., Chernikova L.A., Suponeva N.A., Piradov M.A. Navigated repetitive transcranial magnetic stimulation in treatment of spasticity. Vestnik vosstanovitel'noi meditsiny = Journal of restorative medicine and rehabilitation. 2014;1:80–87.
  33. Suponeva N.A., Piradov M.A., Gnedovskaya E.V. Guillain-Barre syndrome in cities of the Russian Federation: epidemiology, diagnostic and therapeutic possibilities of regional polyclinics. Zdravookhranenie Rossiiskoi Federatsii = Healthcare of Russian Federation. 2013;1:19–25.
  34. Suponeva N.A., Piradov m.A., Gnedovskaya E.V., Bulanova V.A., Baranova N.S., Spirin N.N. Guillain-Barre syndrome in Yaroslavl region: an assessment of diagnostic and treatment facilities. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova = S.S. Korsakov journal of Neurology and Psychiatry. 2013;4:45–49.
  35. Suponeva N.A., Piradov M.A., Nikitin S.S., Timchenko O.L., Gracheva L.A., Bykova L.P., Fed'kina Yu.A., Kostyreva M.V., Shabalina A.A., Grishina D.A. Pathogenetic and prognostic role of autoantibodies to gangliosides of the peripheral nerves in Guillain-Barre syndrome. Annaly klinicheskoi i eksperimental'noi nevrologii = Annals of clinical and experimental neurology. 2013;1:4–11.
  36. Ziganshin R.Kh., Arapidi G.P., Azarkin I.V., Balmasova I.P., Timchenko O.L., Fed'kina Yu.A., Morozova E.A., Piradov M.A., Suponeva N.A., Yushchuk N.D., Govorun V.M. Proteomic technologies for identification of serum biomarkers of potential autoimmune demyelinating polyneuropathies. Bioorganicheskaya khimiya = Bioorganic chemistry. 2011;37(1):36–44.

Views

Abstract - 150

PDF (Russian) - 26

PDF (English) - 1

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.